Biogen’s Alzheimer’s therapy Aduhelm gets updated warning on brain hemorrhage risk:- The U.S. Food and Drug Administration (FDA) has added a new warning to the label of Biogen’s Alzheimer’s therapy Aduhelm (aducanumab) to indicate an increased risk of brain hemorrhages, or bleeding, in patients treated with the drug. The warning is based on the findings from clinical trials, which showed a higher incidence of brain hemorrhages in patients who received Aduhelm compared to those who received a placebo.
The FDA’s decision to approve Aduhelm was controversial and has been the subject of much debate in the medical community, with some experts questioning the drug’s efficacy and safety. The addition of the brain hemorrhage warning is likely to add to the controversy and raise further concerns about the risks of the drug.
It’s worth noting that Aduhelm is the first drug approved by the FDA to treat Alzheimer’s disease in almost 20 years, and it has been hailed as a potentially groundbreaking treatment for a disease that currently has no cure. However, the drug’s high cost and potential risks have led to calls for further research and scrutiny of its use in clinical practice.